Exuma Biotechnology’s Acquisition of CAR-T Assets in China

Cooley advised F1 Oncology affiliate Exuma Biotechnology on its acquisition of rights to novel chimeric antigen receptor T (CAR-T) cell therapy and manufacturing assets in China.

Exuma Biotechnology will develop and commercialize cellular therapies in Greater China to treat solid tumor malignancies. It will also expand its CAR-T cell processing capabilities at a new facility in Shanghai and its viral manufacturing capabilities at a newly constructed facility in Shenzhen.

Exuma Biotechnology is a clinical-stage biotechnology company formed in 2016 to maximize the development and commercialization of enabling products and technology from F1 Oncology in the Greater China markets.

Cooley advised with a team including James Lu (Picture), Jane Adams, Charity Williams, Andrew Harline, Michael Shen and Pan Chen.

Involved fees earner: Jane Adams – Cooley LLP; Pan Chen – Cooley LLP; Andrew Harline – Cooley LLP; James Lu – Cooley LLP; Michael Shen – Cooley LLP; Charity Williams – Cooley LLP;

Law Firms: Cooley LLP;

Clients: EXUMA Biotechnology Co Ltd;